Interview: why the EU Critical Medicines Act brings challenges, but also opportunities

Updated as of: 14 August 2025

The EU’s new Critical Medicines Act may bring extra obligations for pharma companies, but new opportunities will make the investment worth it, according to global pharma and biotech consultant Rashmi Chaturvedi Upadhyay.





Filed under

Topics

Industries